Literature DB >> 29619621

Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response.

Tatsuo Kanda1, Shunichi Matsuoka2, Mitsuhiko Moriyama2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29619621     DOI： 10.1007/s12072-018-9862-1

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  28 in total

Review 1.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

Authors:  Reem Waziry; Behzad Hajarizadeh; Jason Grebely; Janaki Amin; Matthew Law; Mark Danta; Jacob George; Gregory J Dore
Journal:  J Hepatol       Date:  2017-08-09       Impact factor: 25.083

2.  The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.

Authors:  Darrick K Li; Yanjie Ren; Daniel S Fierer; Stephanie Rutledge; Obaid S Shaikh; Vincent Lo Re; Tracey Simon; Abdul-Badi Abou-Samra; Raymond T Chung; Adeel A Butt
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

3.  Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

Authors:  Yasushi Shiratori; Shuichiro Shiina; Takuma Teratani; Masatoshi Imamura; Shun'taro Obi; Shin'pei Sato; Yukihiro Koike; Haruhiko Yoshida; Masao Omata
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

4.  The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.

Authors:  Jee-Fu Huang; Ming-Lun Yeh; Ming-Lung Yu; Chia-Yen Dai; Chung-Feng Huang; Ching-I Huang; Pei-Chien Tsai; Pei-Chen Lin; Yao-Li Chen; Wen-Tsan Chang; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Wan-Long Chuang
Journal:  J Gastroenterol Hepatol       Date:  2015-12       Impact factor: 4.029

5.  New antiviral therapies for chronic hepatitis C.

Authors:  Tatsuo Kanda; Fumio Imazeki; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2010-08-19       Impact factor: 6.047

6.  Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.

Authors:  Antonietta Romano; Paolo Angeli; Sara Piovesan; Franco Noventa; Georgios Anastassopoulos; Liliana Chemello; Luisa Cavalletto; Martina Gambato; Francesco Paolo Russo; Patrizia Burra; Valter Vincenzi; Pier Giorgio Scotton; Sandro Panese; Diego Tempesta; Tosca Bertin; Maurizio Carrara; Antonio Carlotto; Franco Capra; Giada Carolo; Giovanna Scroccaro; Alfredo Alberti
Journal:  J Hepatol       Date:  2018-03-16       Impact factor: 25.083

7.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

Review 8.  APASL consensus statements and recommendation on treatment of hepatitis C.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-04-29       Impact factor: 6.047

9.  HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.

Authors:  George N Ioannou; Pamela K Green; Kristin Berry
Journal:  J Hepatol       Date:  2017-09-05       Impact factor: 25.083

10.  Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Authors:  Tatsuo Kanda; Shin Yasui; Masato Nakamura; Shingo Nakamoto; Koji Takahashi; Shuang Wu; Reina Sasaki; Yuki Haga; Sadahisa Ogasawara; Tomoko Saito; Kazufumi Kobayashi; Soichiro Kiyono; Yoshihiko Ooka; Eiichiro Suzuki; Tetsuhiro Chiba; Hitoshi Maruyama; Fumio Imazeki; Mitsuhiko Moriyama; Naoya Kato
Journal:  Oncotarget       Date:  2018-02-03
View more
  3 in total

1.  Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?

Authors:  Cátia Dias; Filipa Duarte-Ribeiro; Sara Pipa; Ana Rita Barbosa; Margarida Mota; Fernando Rosas Vieira
Journal:  IDCases       Date:  2018-08-30

Review 2.  Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.

Authors:  Maria Guarino; Anna Sessa; Valentina Cossiga; Federica Morando; Nicola Caporaso; Filomena Morisco
Journal:  World J Gastroenterol       Date:  2018-06-28       Impact factor: 5.742

3.  Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals.

Authors:  Devis Pascut; Luisa Cavalletto; Muhammad Yogi Pratama; Silvia Bresolin; Luca Trentin; Giuseppe Basso; Giorgio Bedogni; Claudio Tiribelli; Liliana Chemello
Journal:  Cancers (Basel)       Date:  2019-11-11       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.